ASH 2020 | The Alexander study: AUTO3 with pembrolizumab for R/R DLBCL patients
Aravind Ramakrishnan
• 2 Dec 2020
Aravind Ramakrishnan, MD, BSc, Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center, Austin, TX, discusses the results of Alexander (NCT03287817), a Phase I study aiming to evaluate the efficacy and safety of AUTO3, a novel CD19/22 dual targeting CAR-T cell therapy, with pembrolizumab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research grants: Autolous, Incyte, Kadmon Pharmaceuticals, Kite Pharma, Novartis, Shire Development, Mana Therapeutics, Alpine Immune Sciences, Allovir.
All payments made to institution.
